Detail of "57432-61-8"

Reference

Composition for use in the treatment of puerperal ailments in animals

Composition for use in the treatment of puerperal ailments in animals. Mihailescu, Constantin; Josan, Valentina; Constantinescu, Dan (Intreprinderea de Medicamente, Bucuresti, Rom.). Rom. RO 81659 B 30 Apr 1983, 2 pp. (Romanian). (Romania). CODEN: RUXXA3. CLASS: IC: A61K035-78; A61K035-08. APPLICATION: RO 81-105276 11 Sep 1981. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) A pharmaceutical for treatment of puerperal disorders in animals comprises methylergometrine maleate [57432-61-8] 1, ascorbic acid [50-81-7] 15, acetone Na bisulfite 4, glycerin 100, EtOH 50, nipagin 1, di-Na EDTA 1, and distd. H2O to 1000 parts.

The interaction of the serotonergic and dopaminergic systems on prolactin secretion in the rat

The interaction of the serotonergic and dopaminergic systems on prolactin secretion in the rat. The mechanism of action of the "specific" serotonin receptor antagonist, methysergide. Lamberts, Steven W. J.; MacLeod, Robert M. (Dep. Med., Univ. Virginia Sch. Med., Charlottesville, Va., USA). Endocrinology (Philadelphia), 103(1), 287-95 (English) 1978. CODEN: ENDOAO. ISSN: 0013-7227. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) Section cross-reference(s): 2 The injection of 5-hydroxytryptophan (5-HTP) [56-69-9] into rats increased the serum prolactin (PRL) [9002-62-4] concn. In vitro, the pituitary gland from these rats synthesized and secreted amts. of PRL similar to those produced by nontreated rats. In vitro, a comparable inhibitory effect of 500 nM dopamine [51-61-6] on PRL secretion was obsd. in both control and 5-HTP-injected rats. A significant increase in PRL synthesis was obsd. in glands from 5-HTP-treated rats when the pituitaries were incubated in the presence of dopamine. Neither 5-HTP nor serotonin [50-67-9] had a direct in vitro effect on PRL secretion. It is suggested that serotonin precursors exert their stimulatory effect on PRL secretion via the hypothalamus and not at the pituitary gland. Administration of methysergide (I) [361-37-5] caused an early increase in serum PRL; however, after 2-4 h, a significant inhibitory effect was produced by the drug. The in vitro secretion of PRL was greatly decreased by the prior injection of I. This was completely blocked by the coadministration of haloperidol. Dopamine was less able to decrease the in vitro secretion of PRL when the animals were injected with I 15 min earlier. I had no direct in vitro effect on PRL secretion. It did, however, completely block the dopamine-mediated inhibition of PRL secretion. Methergine [57432-61-8], the demethylated metabolite of I, inhibited the in vitro secretion of PRL and this effect was completely blocked by coincubation with haloperidol. Thus, serotonin is stimulatory to the brain-neuroendocrine system which stimulates the secretion of PRL. The mechanisms through which serotonin and I act to modify PRL secretion are very complex and may act by influencing the dopaminergic system. The initial response after I injection is stimulatory to PRL secretion by blockade of the dopamine receptor, and subsequently, the metabolites of the drug inhibit secretion of the hormone by stimulating the pituitary dopaminergic system.